TREAT EARLY TODAY FOR HER TOMORROW1–4

Hear from Lucy, a real patient living with AS

 In this video, Lucy talks about the different symptoms she’s experienced and the impact her condition has had on her daily life. She also discusses other aspects of living with AS.

FootnotesSafety Profile

alt

The use of adequate contraception should be considered for women of childbearing potential. For women planning pregnancy, continued contraception may be considered for 5 months after the last CIMZIA® dose due to its elimination rate, but the need for treatment of the woman should also be taken into account. Data from more than 1,300 prospectively collected pregnancies exposed to CIMZIA® with known pregnancy outcomes, including more than 1,000 pregnancies exposed during the first trimester, does not indicate a malformative effect of CIMZIA®. Further data are being collected as the available clinical experience is still limited to conclude that there is no increased risk associated with CIMZIA® administration during pregnancy. CIMZIA® should only be used during pregnancy if clinically needed. CIMZIA® can be used during breastfeeding.1

Related information

Velit adipisicing adipisicing nostrud irure ullamco sint do veniam in nulla nulla pariatur eu id. Cupidatat mollit adipisicing eiusmod Lorem cupidatat qui est do cillum duis aliqua id do ullamco.

Video10 min
Patient perspectives video slider 1

Lorem ipsum dolor sit amet consectetur. Risus fusce egestas ipsum turpis turpis. Amet interdum facilisis risus ut sit. Ut metus nulla nisl elementum pellentesque.

IE-P-BR-EPOS-2200144, July 2022
Reumatologi
Watch video
Video10 min
Patient perspectives video slider 2

Lorem ipsum dolor sit amet consectetur. Risus fusce egestas ipsum turpis turpis. Amet interdum facilisis risus ut sit. Ut metus nulla nisl elementum pellentesque.

IE-P-BR-EPOS-2200144, July 2022
Reumatologi
Watch video
Video10 min
Patient perspectives video slider 3

Lorem ipsum dolor sit amet consectetur. Risus fusce egestas ipsum turpis turpis. Amet interdum facilisis risus ut sit. Ut metus nulla nisl elementum pellentesque.

IE-P-BR-EPOS-2200144, July 2022
Reumatologi
Watch video
Video10 min
Patient perspectives video slider 4

Lorem ipsum dolor sit amet consectetur. Risus fusce egestas ipsum turpis turpis. Amet interdum facilisis risus ut sit. Ut metus nulla nisl elementum pellentesque.

IE-P-BR-EPOS-2200144, July 2022
Reumatologi
Watch video

Title of this section

Title of this content. CIMZIA® demonstrated sustained remission

Footnotes

alt

CIMZIA® safety profile

The use of adequate contraception should be considered for women of childbearing potential. For women planning pregnancy, continued contraception may be considered for 5 months after the last CIMZIA® dose due to its elimination rate, but the need for treatment of the woman should also be taken into account. Data from more than 1,300 prospectively collected pregnancies exposed to CIMZIA® with known pregnancy outcomes, including more than 1,000 pregnancies exposed during the first trimester, does not indicate a malformative effect of CIMZIA®. Further data are being collected as the available clinical experience is still limited to conclude that there is no increased risk associated with CIMZIA® administration during pregnancy. CIMZIA® should only be used during pregnancy if clinically needed. CIMZIA® can be used during breastfeeding.1

Safety profile

You may also like…

alt

Name of the page

alt

Name of the page

Abbreviated Prescribing Information

Click here

Abbreviations 

AS: Ankylosing spondylitis; KOL: Key opinion leader; PsA: Plaque psoriasis; PSO: Psoriasis; RA: Rheumatoid arthritis.

References

1. CIMZIA® Summary of Product Characteristics, July 2022. Last accessed 22/12/2022. Access the CIMZIA® SmPC

2. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2):228-233.

3. Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890-1896.

4. Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE. Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep. 2018 May 12;20(6):35.

CIMZIA® Indication

CIMZIA®, in combination with methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis in adults:

  • For the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. CIMZIA® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate
  • For the treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs. 

CIMZIA® has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with MTX.

CIMZIA® is indicated for the treatment of adult patients with severe active axial spondyloarthritis comprising:​

  • Adults with severe active ankylosing spondylitis (AS) who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs)​
  • Adults with severe active axial spondyloarthritis without radiographic evidence of AS (nr-axSpA) but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have had an inadequate response to, or are intolerant to NSAIDs ​

CIMZIA®, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate. CIMZIA® can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate​

CIMZIA® is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

EU-P-CZ-PsA-2200001

Date of preparation: February 2023

Har du någon fråga?

Välkommen att boka en tid med en UCB representant för att diskutera dina frågor mer i detalj.

Detta formulär skall ej användas för att rapportera någon biverkan eller produktreklamation. Om du önskar göra detta vänligen gör det via de sedvanliga kanalerna eller kontakta oss via formuläret här.